Sarcoidosis (SA) is a multisystem granulomatous disease with a highly variable clinical course. To-date, there are no validated circulating biomarkers capable of reliably predicting long-term outcome in SA [1]. Identifying accessible, routinely measurable metabolic indices that could improve risk stratification in SA therefore represents an unmet clinical need of considerable importance.
